Astrantus’s Repligen RGEN Stock Holding History

Astrantus’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,800	Closed	-$1.01M	–	277
2021 Q4	$1.01M	Buy	+3,800	New	+$1.02M	0.75%	34

Other funds holding RGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Astrantus's RGEN Position: Q1 2022 in Review

Astrantus sold out of Repligen (RGEN) in Q1 2022, closing a stake of 3,800 shares — an estimated $1.01M sold.

Astrantus first reported a position in RGEN in Q4 2021 and held it in 1 quarter. The position peaked at $1.01M in Q4 2021. 450 funds tracked by Wall St. Rank hold RGEN as of Q1 2022.

Astrantus reported no remaining Repligen position as of Q1 2022 after selling out during the quarter.
Astrantus sold 3,800 Repligen shares in Q1 2022, an estimated $1.01M.
Astrantus first reported a position in Repligen in Q4 2021 and held it in 1 quarter.
Astrantus's Repligen position peaked at $1.01M in Q4 2021.
450 funds tracked by Wall St. Rank held Repligen as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.